Abstract:Photoresponsive ruthenium (Ru) complexes have been extensively studied in the photodynamic therapy (PDT) of cancer. The metal-to-ligand charge transfer (MLCT) absorption maximum of most Ru complexes is located in the short-wavelength visible region, which is well suited for superficial tumors but shows inefficient therapeutic effects for more deep-seated ones. Moreover, Ru complexes are primarily located in the mitochondria or nucleus, always resulting in high levels of dark toxicity and DNA mutation. Herein, we reported a new ruthenium complex (Ru-I) for red-light-triggered PDT. The activation wavelength of Ru-I is successfully extended to 660 nm. Importantly, the complex photosensitizer can be quickly taken up by cancer cells and selectively accumulated in the lysosome, an ideal localization for PDT purposes. Intratumoral injection of Ru-I into tumor-bearing mice achieved excellent therapeutic effects and thus holds great promise for applications in lysosome localization photodynamic therapy.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.0c22551?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.0c22551</a>.Experimental details including synthetic methods of Ru-I and characterization; ESI-HRMS spectrum of compound 3 (Figure S1); 1H NMR spectrum of compound 3 (Figure S2); ESI-HRMS spectrum of compound 4 (Figure S3); 1H NMR and 13C NMR spectra of compound 4 (Figure S4); purity of Ru-I measurement by HPLC (Figure S5); HOMO and LUMO orbitals for Ru-I (Figure S6); absorption and emission spectrum of Ru-I in different solvents (Figure S7); stability of Ru-I with different treatments (Figures S8 and S9); ROS generation analysis (Figures S10–S12); cell imaging experiments (Figures S13–S17); in vitro photocytotoxicity evaluation (Figures S18–S20); and animal experiments (Figures S21 and S22) (<a class="ext-link" href="/doi/suppl/10.1021/acsami.0c22551/suppl_file/am0c22551_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Development of Ruthenium Nanophotocages with Red or Near‐Infrared Light‐Responsiveness

Red-Light-Responsive Ru Complex Photosensitizer for Lysosome Localization Photodynamic Therapy

A Near‐Infrared Light‐Activated Photocage Based on a Ruthenium Complex for Cancer Phototherapy

The Development of Ru(II)-Based Photoactivated Chemotherapy Agents.

7401 Development and Evaluation of Ruthenium-based Photoactivated Chemotherapeutic Agents

Inside Back Cover: A Near‐Infrared Light‐Activated Photocage Based on a Ruthenium Complex for Cancer Phototherapy (Angew. Chem. Int. Ed. 24/2023)

A Tailored Multifunctional Anticancer Nanodelivery System for Ruthenium‐Based Photosensitizers: Tumor Microenvironment Adaption and Remodeling

Innenrücktitelbild: A Near‐Infrared Light‐Activated Photocage Based on a Ruthenium Complex for Cancer Phototherapy (angew. Chem. 24/2023)

Ruthenium Complex-Modified Carbon Nanodots For Lysosome-Targeted One- And Two-Photon Imaging And Photodynamic Therapy

Photoresponsive ruthenium-containing polymers: potential polymeric metallodrugs for anticancer phototherapy.

A 700 Nm LED Light Activated Ru(II) Complex Destroys Tumor Cytoskeleton Via Photosensitization and Photocatalysis

Photoactivation of Anticancer Ru Complexes in Deep Tissue: How Deep Can We Go?

Ruthenium photosensitizer anchored gold nanorods for synergistic photodynamic and photothermal therapy

Theranostic TEMPO-functionalized Ru(ii) Complexes As Photosensitizers and Oxidative Stress Indicators

Ruthenium(Ii) Complex Incorporated Uio-67 Metal-Organic Framework Nanoparticles for Enhanced Two-Photon Fluorescence Imaging and Photodynamic Cancer Therapy

Drug Therapy: an Amphiphilic Ruthenium Polymetallodrug for Combined Photodynamic Therapy and Photochemotherapy in Vivo (adv. Mater. 6/2017)

Red-Emissive Ruthenium-Containing Carbon Dots for Bioimaging and Photodynamic Cancer Therapy

Development of Ruthenium Complexes with O2-Independent Activity for Photochemotherapy

Ruthenium(II) Polypyridyl Complexes As Mitochondria-Targeted Two-Photon Photodynamic Anticancer Agents

Photoactivated full-API nanodrug (FAND): Harnessing Transition Metal Complexes and MTH1 Inhibitor for Enhanced DNA Damage in Cancer Cells